By Helena R. Berger, Executive Vice President & CEO, American Association of People with Disabilities
The future of medicine is biologic drugs. Not only have they revolutionized the medical treatments of serious diseases, they have also transformed treatments for many people with disabilities – from offering new promise to people with multiple sclerosis to aiding those with debilitating arthritis.
A lot has been written about how the Food and Drug Administration may soon approve biosimilars, the first attempted copies of biologics. But as part of an ongoing commitment to support efforts to assure accessible, high-quality and affordable health care for people with disabilities, we must ensure that patient safety is at the forefront of public policy discussions as they relate to their approval and usage.